497 related articles for article (PubMed ID: 7898101)
1. Nilvadipine: profile of a new calcium antagonist. An overview.
Rosenthal J
J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S92-107. PubMed ID: 7898101
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of nilvadipine, a new dihydropyridine-type calcium antagonist.
Honerjäger P; Seibel K
J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S15-21. PubMed ID: 1283184
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of nilvadipine.
von Nieciecki A; Huber HJ; Stanislaus F
J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S22-9. PubMed ID: 1283185
[TBL] [Abstract][Full Text] [Related]
4. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
[TBL] [Abstract][Full Text] [Related]
5. 24-hour blood pressure control after single daily doses of nivaldipine in patients with essential hypertension.
Lossnitzer K; Huber HJ; Kuchlbauer R; Quitzdorff G
J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S35-42. PubMed ID: 1283187
[TBL] [Abstract][Full Text] [Related]
6. Effects of nilvadipine on the cardiovascular system in experimental animals.
Ohtsuka M; Koibuchi Y; Sakai S; Tsujioka K; Fujiwara T; Ozaki T; Maeda K; Motoyama I; Horiai H; Ono T
Arzneimittelforschung; 1988 Nov; 38(11):1605-18. PubMed ID: 3214444
[TBL] [Abstract][Full Text] [Related]
7. Amlodipine: a once daily calcium antagonist.
Burges RA
J Hum Hypertens; 1991 Aug; 5 Suppl 1():49-54. PubMed ID: 1834846
[TBL] [Abstract][Full Text] [Related]
8. Nilvadipine in hypertension with renal dysfunction.
Berger HH; Albert FW
J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S73-9. PubMed ID: 1283194
[TBL] [Abstract][Full Text] [Related]
9. Nilvadipine. A review of its pharmacodynamic and pharmacokinetic properties, therapeutic use in hypertension and potential in cerebrovascular disease and angina.
Brogden RN; McTavish D
Drugs Aging; 1995 Feb; 6(2):150-71. PubMed ID: 7711361
[TBL] [Abstract][Full Text] [Related]
10. Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial.
Leonetti G;
Curr Med Res Opin; 2005 Jun; 21(6):951-8. PubMed ID: 15969895
[TBL] [Abstract][Full Text] [Related]
11. The tolerability of nilvadipine compared to nifedipine in patients with essential hypertension.
Faust G
J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S56-61. PubMed ID: 1283191
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses.
van Zwieten PA; Pfaffendorf M
J Hypertens Suppl; 1993 Dec; 11(6):S3-8. PubMed ID: 8169379
[TBL] [Abstract][Full Text] [Related]
13. Benidipine hydrochloride--a new calcium-channel blocker of the dihydropyridine type. Pharmacokinetics, pharmacodynamics, tolerance and dose finding in mild to moderate hypertension.
Maier-Lenz H; Rode H; Lenau H; Thieme G; Wölke E; Kobayashi H; Kobayashi S; Oka T
Arzneimittelforschung; 1988 Nov; 38(11A):1757-63. PubMed ID: 3219156
[TBL] [Abstract][Full Text] [Related]
14. The pharmacological properties of lipophilic calcium antagonists.
van Zwieten PA
Blood Press Suppl; 1998; 2():5-9. PubMed ID: 9850436
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive and cardiovascular effects of the new dihydropyridine derivative methyl (E)-3-phenyl-2-propen-1-yl-1,4-dihydro-2,6-dimethyl- 4-(3-nitrophenyl)pyridine-3,5-dicarboxylate.
Yamaura T; Kase N; Kita H; Uematsu T
Arzneimittelforschung; 1986; 36(1):29-34. PubMed ID: 3754142
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular activities of the new potent and long-lasting antihypertensive calcium entry blocker (+-)-3-ethyl,5-methyl,2- ([2-(formylamino)-ethyl]- thiomethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicar box ylate.
Germini M; Passoni A; Casciarri I; Bosetti P; Piazzoni L; Cazzulani P; Gandolfi CA; Tofanetti O; Ceserani R
Arzneimittelforschung; 1992 Jan; 42(1):1-8. PubMed ID: 1586373
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive effects of the new calcium antagonist benidipine hydrochloride in rats.
Karasawa A; Kubo K; Shuto K; Oka T; Nakamizo N
Arzneimittelforschung; 1988 Nov; 38(11A):1684-90. PubMed ID: 3064752
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy of nilvadipine and nitrendipine on circadian blood pressure.
Keck M
J Cardiovasc Pharmacol; 1992; 20 Suppl 6():S43-9. PubMed ID: 1283188
[TBL] [Abstract][Full Text] [Related]
20. [Amlodipine: pharmacokinetic and pharmacodynamic profile of a calcium antagonist with prolonged effect].
Heynen G
Schweiz Rundsch Med Prax; 1992 Feb; 81(7):199-203. PubMed ID: 1531545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
